COMMUNIQUÉS West-GlobeNewswire

ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
05/12/2017
OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or prevent preterm birth Geneva, Switzerland and Boston, MA - December 5, 2017 - ObsEva [...]
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
05/12/2017
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally active dual PI3K delta/ [...]
Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017
05/12/2017
-Company announces vecabrutinib as generic name for SNS-062- -Event on December 9 in Atlanta, GA with Slide Webcast- SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: [...]
Cianna Medical Launches Comprehensive Support Program to Support Health Systems’ Mission of ‘Moving Beyond Wires’ for Breast Tumor Localization
05/12/2017
ALISO VIEJO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, today announced the launch of SCOUT Care ™ , a comprehensive training, certification and [...]
Arog Pharmaceuticals Announces Oral Presentation on Crenolanib at the 2017 American Society of Hematology Annual Meeting
05/12/2017
DALLAS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet [...]
Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors
05/12/2017
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of [...]
Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting
05/12/2017
40 mg dose showed statistically significant improvement on Cogscreen objective cognitive measures of attention and memory Two additional self-rated secondary endpoints (CPFQ and QIDS) showed statistically significant [...]
Clementia Announces Date of Corporate Update Conference Call
05/12/2017
MONTREAL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), a clinical-stage biopharmaceutical company, today announced that management will host a conference call and webcast at 8:30 a.m [...]
Clementia Annonce la Date de la Conférence Téléphonique sur sa Mise à Jour Corporative
05/12/2017
MONTRÉAL, 05 déc. 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui que la direction tiendra une conférence téléphonique et [...]
Biodesix Leaders Share Commercial and Pipeline Updates at Annual qPCR and dPCR Congress
05/12/2017
BOULDER, Colo., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Biodesix provided updates and data related to the company’s on-market and in-development liquid biopsy tests at the 2017 qPCR & Digital PCR Congress in London, UK [...]
Transactions in relation to share buyback program
05/12/2017
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico
05/12/2017
VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. ( “CTL” ) [...]
Update on NeuroSearch’s business status and future
05/12/2017
Company announcement 5 December 2017 In the annual report for 2016, the Board of Directors informed that the Company would continue the work to dispose its remaining assets and liabilities, and that a sale of the [...]
Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing
05/12/2017
THE WOODLANDS, Texas, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that it has entered into a definitive term loan agreement with BioPharma Credit PLC and BioPharma [...]
Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial
05/12/2017
Abu Dhabi, UAE, 5 December 2017 - Once-daily Xultophy ® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by [...]
Probiodrug AG: Probiodrug and Crossbeta Biosciences extend their strategic partnership in the field of Alzheimer's disease biomarkers
05/12/2017
HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), and the [...]
Beleave Receives License to Produce Cannabis Oils from Health Canada
05/12/2017
TORONTO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (" Beleave " or the " Company ") (CSE:BE)( OTCQX:BLEVF) is pleased to announce it has been granted a license by Health Canada to begin commercial production of [...]
Triphase Accelerator to Present Investigational New Drug Enabling Data for TRPH-222
04/12/2017
TORONTO and SOMERSET, N.J., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading [...]
NTS Ventures and IHMA Announce a Collaborative Agreement to Provide an Extensive Suite of Clinical Mycology, Antifungal and Microbiology Laboratory Services to Support Anti-infective Drug Development to the Biopharmaceutical Industry
04/12/2017
SCHAUMBURG, Ill., Dec. 04, 2017 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service [...]

Pages